Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza a viruses

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Nguyen, Jack T ^a   Smee, Donald F ^b   Barnard, Dale L ^b   Julander, Justin G ^b   Gross, Matthew ^a   de Jong, Menno D ^c   Went, Gregory T ^a  

^a Adamas Pharmaceuticals Inc   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; PLACEBO; RIBAVIRIN; ANTIVIRUS AGENT;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; IN VIVO STUDY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORTALITY; MOUSE; NONHUMAN; THERAPY DELAY; VIRUS INFECTIVITY; WEIGHT REDUCTION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; DISEASE MODEL; DOG; DRUG COMBINATION; EVALUATION; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

INFLUENZA A VIRUS; MUS;

AMANTADINE; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOGS; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; FEMALE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PLACEBOS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84856078603     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031006     Document Type: Article

References (37)

1. Machado CM, Boas LS, Mendes AV, da Rocha IF, Sturaro D, et al. (2004) Use of Oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 34: 111-114.
2. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, et al. (2007) Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 45: 1568-1575.
3. Nichols WG, Guthrie KA, Corey L, Boeckh M, (2004) Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39: 1300-1306.
4. Choi SM, Boudreault AA, Xie H, Englund JA, Corey L, et al. (2011) Differences in clinical outcomes following 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 117: 5050-5056.
5. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, et al. (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51: 123-129.
6. Kandun IN, Tresnaningsih E, Purba WH, Lee V, Samaan G, et al. (2008) Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 372: 744-749.
7. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC, (2009) Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 199: 1435-1441.
8. Renaud C, Boudreault AA, Kuypers J, Lofy KH, Corey L, et al. (2011) H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients. Emerg Infect Dis 17: 653-660.
9. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203-1207.
10. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
11. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759-765.
12. Li CC, Wang L, Eng HL, You HL, Chang LS, et al. (2010) Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis 16: 1265-1272.
13. Ward P, Small I, Smith J, Suter P, Dutkowski R, (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55 (Suppl 1): i5-i21.
14. Centers for Disease Control and Prevention (2010) 2010-2011 Influenza Season Week 49 ending December 11, 2010. http://wwwcdcgov/flu/weekly/indexhtm.
15. Centers for Disease Control and Prevention (2009) Update: influenza activity-United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine. MMWR Morb Mortal Wkly Rep 58: 369-374.
16. Sheu TG, Fry AM, Garten RJ, Deyde VM, Shwe T, et al. (2011) Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A(H1N1) Viruses: 2008-2010. J Infect Dis 203: 13-17.
17. van der Vries E, van den Berg B, Schutten M, (2008) Fatal oseltamivir-resistant influenza virus infection. N Engl J Med 359: 1074-1076.
18. Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, et al. (2009) Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 53: 4115-4126.
19. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, et al. (2010) Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5: e9332.
20. Govorkova EA, Fang HB, Tan M, Webster RG, (2004) Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 48: 4855-4863.
21. Hayden FG, (1986) Combinations of antiviral agents for treatment of influenza virus infections. J Antimicrob Chemother 18 (Suppl B): 177-183.
22. Hayden FG, Douglas RG Jr, Simons R, (1980) Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 18: 536-541.
23. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA, (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70: 121-131.
24. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, et al. (2008) Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 52: 3889-3897.
25. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA, (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12: 363-370.
26. Madren L, Shipman C, Hayden F, (1995) In vitro inhibitory effects of combinations of anti-influenza agents. Antiviral Chemistry & Chemotherapy 6: 109-113.
27. Masihi KN, Schweiger B, Finsterbusch T, Hengel H, (2007) Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice. J Chemother 19: 295-303.
28. Smee DF, Bailey KW, Morrison AC, Sidwell RW, (2002) Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 48: 88-93.
29. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD, (2009) Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 53: 2120-2128.
30. Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, et al. (2010) Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 7: e1000362.
31. Rebetol Official FDA Information. Available: http://www.drugscom/pro/rebetol.html. Accessed 2012 Jan 3.
32. Tamiflu Official FDA Information. Available: http://www.drugscom/pro/tamiflu.html. Accessed 2012 Jan 3.
33. Vernier VG, Harmon JB, Stump JM, Lynes TE, Marvel JP, et al. (1969) The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol Appl Pharmacol 15: 642-665.
34. Ilyushina NA, Govorkova EA, Russell CJ, Hoffmann E, Webster RG, (2007) Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus. J Gen Virol 88: 1266-1274.
35. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD, (2003) Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 77: 8418-8425.
36. Lau J, (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35: 1002-1009.
37. Kjaergard LLKK, Gluud C, (2001) Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 323: 1151-1155.